Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vycor Medical (VYCO) EPS (Weighted Average and Diluted) (2022 - 2025)

Vycor Medical has reported EPS (Weighted Average and Diluted) over the past 4 years, most recently at -$0.0 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 816.87% to -$0.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.01 through Dec 2025, up 50.0% year-over-year, with the annual reading at -$0.01 for FY2025, 0.0% changed from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.0 for Q4 2025 at Vycor Medical, up from -$0.0 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.0 in Q2 2023 and troughed at -$0.01 in Q3 2023.
  • The 4-year median for EPS (Weighted Average and Diluted) is -$0.0 (2022), against an average of -$0.0.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 300.8% in 2025 against a maximum downside of 816.87% in 2025.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.0 in 2022, then rose by 22.35% to -$0.0 in 2023, then soared by 92.82% to -$0.0 in 2024, then tumbled by 816.87% to -$0.0 in 2025.
  • Per Business Quant, the three most recent readings for VYCO's EPS (Weighted Average and Diluted) are -$0.0 (Q4 2025), -$0.0 (Q3 2025), and $0.0 (Q2 2025).